source
- Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity assetRoche is spending $190 million upfront to license a non-incretin obesity drug from South Korea’s Hanmi Pharm. The deal represents the latest in a string of obesity pacts inked by Roche in recent ye…Endpoints · 17m ago↗ source
- Option-to-acquire deals remain rare in biotech's buzzy M&A seasonTwo recent deals are focusing attention on a relatively rare structure for biotech buyouts: the option-to-acquire. Drug developers are on pace to have one of the best dealmaking years in industry h…Endpoints · 43m ago↗ source
- Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismRoche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.